TITLE

Pralatrexate Injection (FolotynTM)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
November 2009
SOURCE
Internal Medicine Alert;11/15/2009, Vol. 31 Issue 21, p165
SOURCE TYPE
Periodical
DOC. TYPE
Product Review
ABSTRACT
The article evaluates Pralatrexate, an injection of an inhibitor of dihydrofolate reductase for treatment of relapsed or refractory peripheral T-cell lymphoma, from Allos Therapeutics Inc.
ACCESSION #
46738306

 

Related Articles

  • Earnings Roundup.  // BioWorld Today;8/8/2011, Vol. 22 Issue 152, p2 

    This article reports on the financial performance of Allos Therapeutics Inc. in the second quarter of 2011.

  • Earnings Roundup.  // BioWorld Today;3/8/2012, Vol. 23 Issue 46, p7 

    The article reports on the 17% increase in the net product sales of Allos Therapeutics Inc. during the fourth quarter of 2011.

  • Earnings Roundup.  // BioWorld Today;11/4/2011, Vol. 22 Issue 215, p7 

    The article reports on the financial performance of Allos Therapeutics Inc. of Westminster, Colorado for the third quarter of 2011.

  • Allos Slides on Slow Folotyn Sales, Foggy Data.  // Bioworld Week;8/2/2010, Vol. 18 Issue 31, p4 

    The article reports the 15.3 percent decline of the shares of Allos Therapeutics Inc after the biotech revealed lower-than-expected second-quarter sales of peripheral T-cell lymphoma drug Folotyn and top-line data from a Phase IIb lung cancer trial whichlacked detail.

  • EARNINGS ROUNDUP.  // BioWorld Today;3/3/2010, Vol. 21 Issue 41, p7 

    The article reports on the increase in the sales of Folotyn (pralatrexate), designed for patients with relapsed or refractory peripheral T-cell lymphoma, from Allos Therapeutics Inc. for the fourth quarter of 2009.

  • Allos Therapeutics to Report 4th Qtr and Full Year 2011 Results on March 6 2012.  // Biomedical Market Newsletter;2/21/2012, Vol. 21, p1 

    The article offers information on a conference call to be hosted by Allos Therapeutics Inc. on March 6, 2012 in which it will release its financial results for the fourth quarter and full year (FY) ended December 31, 2011.

  • Allos' Brain-Cancer Therapy Trial Misses Endpoints.  // Bioworld Week;6/25/2007, Vol. 15 Issue 26, p4 

    The article reports on the failure of Allos Therapeutics Inc.'s Phase III trial with Efraproxyn for brain cancer that has metastasized from the breast. The company and investors set the compound aside in favor of the dihydrofolate reductase (DHFR) inhibitor in Phase II trials against relapsed or...

  • Stock Movers.  // BioWorld Today;5/7/2010, Vol. 21 Issue 88, p2 

    A list of biotechnology companies and the changes in their stocks is presented including NASDAQ Biotechnology, Aeterna Zentaris Inc. and Allos Therapeutics Inc.

  • Earnings Roundup.  // BioWorld Today;11/8/2010, Vol. 21 Issue 216, p2 

    This section offers news briefs on earnings of biotechnology companies for the third quarter of 2010, including Allos Therapeutics Inc., which posted sales of 8.2 million U.S. dollars, and Amylin Pharmaceuticals Inc., which reported a net product sales of 154 million U.S. dollars.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics